Royalty Report: Drugs, Cancer, Delivery – Collection: 260369

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Cancer
  • Delivery
  • Disease
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 260369

License Grant
The University grants to Licensee a world-wide exclusive license under certain Regents Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.

The University grants to Licensee a world-wide co-exclusive license under other certain Regents Patent Rights to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law.

License Property
Certain inventions are generally characterized as
—  lmmunoliposomes that Optimize Internalization into Target Cells;
—  Preparation of Stable Formulations of Liposome-Plasrnid DNA Complexes for Efficient In Vivo Gene Delivery;
—  Protein-Conjugated Lipidic Microparticles;
—  Method for Selection of Internalizing Antibodies; and,
—  Method for Selecting Cell Binding and Internalizing Ligands.
Field of Use
Licensee is a biotechnology company developing lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy.

IPSCIO Record ID: 261812

License Grant
Under a separate Agreement and Amendment, between the University and a Third Party, the Third Party granted to The University Regents a nonexclusive license to conduct Activities under the Third Party Patent Rights. Third Party also grants to The Regents under such non-exclusive license the right to grant sublicenses to one third party and its affiliates as affiliate is defined in the Agreement and Amendment.

The Regents and Licensee now wish to amend their Agreement to grant Licensee a sublicense to the Third Party Patent Rights and to amend certain other provisions of the Agreement in accordance with the terms of the Agreement and Amendment.

This amendment adds
—  the exclusive license granted to Licensee is reduced to a non-exclusive license to the extent of the grant of rights to Third Party by The Regents to conduct Activities under the Agreement and Amendment.

—  subject to the limitations set forth in this Agreement, The Regents grants to Licensee a non-exclusive license to make, have made, use, sell, offer to sell and import Licensed Product and to practice Licensed Method to the extent permitted by law under its non-exclusive license under the Third Party Patent Rights granted under the Agreement and Amendment.

License Property
The patents relate to Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery.

The Third Party Product will mean a product developed under the Program which is composed of the Targeting Technology and the Internalizing Technology combined with a System containing doxorubicin, with or without the Micellar Conjugation Technology,

Internalizing Technology will mean Hermes proprietary cellular internalization technology solely to the extent that it relates to the internalization of a targeted liposome containing doxorubicin into a tumor cell.

Micellar Conjugation Technology will mean the standard operating procedure used by Lcensee and/or the National Cancer Institute for linking the Targeting Technology to pegyiated liposomes.

Field of Use
Licensee is a biotechnology company developing lipidic nano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy.

IPSCIO Record ID: 260370

License Grant
The Regents grants to the Licensee a license under its rights in and to Patent Rights to make, have made, use, Sell, offer for Sale and import Licensed Products and to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

The Regents grants to the Licensee a license under its rights in and to Property Rights to make, have made and use the Biological Materials to make, have made, use, Sell, offer for Sale and import Licensed Products, or to practice Licensed Methods, in the United States and in other countries where The Regents may lawfully grant such licenses, only in the Field of Use.

License Property
The Certain inventions are generally characterized as
—  High Affinity Human Antibodies to Novel Tumor Antigens;
—  Bi-specific Single Chain Fv scFv Antibody Molecule; and,
—  Human Erb-B Antibodies.
Field of Use
The Field of Use means use as a therapeutic or diagnostic in humans. The Field of Use specifically excludes providing Licensed Services to third parties; the Sale, transfer, lease, exchange or other disposition or provision of Biological Materials, other than as incorporated in Licensed Products for Sale or as expressly permitted in this Agreement; the making, using or Selling of Biological Materials or Licensed Products for use in drug discovery or as a research reagent (other than for the development of Licensed Products);  the making, using or Selling of Non-Patent Products; and (v) all other uses and applications of Biological Material or Licensed Products, except as expressly permitted in this Agreement.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.